AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02439528 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic analysis
Description: One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.~The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis.
Study NCT02888418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)
Description: Injection vaccine produced by Beijing institute of biological products co., LTD, containing HPV antigen protein, 120μg/0.5ml/bottle
Study NCT02888418 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02764424 — intervention group
Intervention type: DEVICE
Intervention: NIPE (MDoloris®)
Description: Each file consists of a simultaneous recording of an electrocardiogram signal according to usual practice (cardiac monitor PHILIPS), coupled with a concomitant registration of NIPE (Newborn Infant Parasympathetic Evaluation - MDoloris®). The electrocardiogram signal, respiration rate, oxygen saturation (SpO2) and NIPE are recorded simultaneously on a computer with a capture card. The other indices of Heart Rate Variability will be analyzed offline.
Study NCT00910143 — intervention group
Intervention type: PROCEDURE
Intervention: conventional rectal surgery
Description: type of rectal surgery before the introduction of TME
Study NCT00910143 — intervention group
Intervention type: PROCEDURE
Intervention: total mesorectal excision
Description: total mesorectal excision
Study NCT05055284 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electromyographic-biofeedback guided (EMG-BF) isometric quadriceps strengthening with patellar taping five days a week for six weeks.
Description: Patellar Taping, electromyography biofeedback (EMG-BF), Strength Training
Study NCT05055284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromyographic-biofeedback guided (EMG-BF) isometric quadriceps strengthening with patellar taping five days a week for six weeks.
Description: Patellar Taping, electromyography biofeedback (EMG-BF), Strength Training
Study NCT04090099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spina plane block
Description: While the patient is in the sitting position, an area containing 2 cm lateral of the T5 spinous process will be cleaned with povidone iodine. A high frequency ultrasound linear probe covered with a sterile sheath will be placed 2 cm to the side of the T5 spinous process, first to the right or left. After demonstrating the T5 transverse process and the erector spinae muscle on top, the 22-gauge, 80 mm insulated Quincke-type needle will be inserted into the skin at an angle of about 30 degrees from the cranial to the caudal, using an in-plane technique. When the transverse process is touched, the needle is withdrawn and after a negative aspiration test with 0.5 mL of normal saline and after a hypo-echogenic display and hydrodissection, a local anesthetic solution will be applied to the fascia under the erector spinae muscle.
Study NCT00006103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00006103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00006103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT02402959 — intervention group
Intervention type: OTHER
Intervention: individualized treatment
Description: Individualized treatment includes anything no matter what kind of interventions, like medicine, herbs, acupuncture, massage, behaviour therapy, diet and exercise therapy. The TCM experts should choose the intervention in accordance to the patients' preference, best existed evidence and their empirical knowledge.
Study NCT04444206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound cervical length screening
Description: Cervical lenght and Consistence Cervical Index measurements performed, between 11 and 13 weeks + 6 days, in the , between 19 and 22 weeks and i between 29 and 32 weeks during the ultrasound examinations required by the monitoring routine of pregnancy.
Study NCT01454310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wound coverage by acellular skin substitute
Description: Burn wounds are covered by an acellular skin substitute and remains 10-14 days that peals away in line with re-epithelialisation
Study NCT01454310 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous skin
Description: Matched burn wound is covered by autologous skin after tangential excision.
Study NCT02286830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.
Study NCT01761227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fufangdanshen Tablets
Description: 1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
Study NCT01761227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 3 tablets per time, 3 times per day for 24 weeks
Study NCT02762604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagined Gait Intervention
Description: Phone-based imagined gait intervention: participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
Study NCT02762604 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual Imagery Intervention
Description: Phone-based visual imagery intervention: participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
Study NCT03568617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The subjects will receive 20 trains of 100 stimuli each delivered at 10 Hz and 80% of MT over the left MC (M1), 3 days a week, for 4 weeks.
Study NCT04364438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Muscle Stimulation
Description: EMS is believed to produce some inhibition of the bladder, allowing the bladder to reach a greater volume. This is believed to occur because electrical stimulation also stimulates nerves in the pelvic floor. In most people, bladder voiding is inhibited when the skin of the pelvis is touched or otherwise manipulated. This inhibition is via a reflex in the spinal cord that may have evolved to inhibit voiding during sexual contact. The pelvic floor nerves are responsible for transmitting the sensation of touch from the pelvis to the spinal cord. Electrical stimulation of these nerves thus activates sensory fibers that cause inhibition of bladder voiding via a reflex mechanism in the spinal cord. This may explain EMS is an effective treatment for people with incontinence.
Study NCT04364438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electric Nerve Stimulation
Description: TENS is based on the gate control theory of abolishing the local micturition reflex arc. It is a non-pharmacological method of inhibiting the presynaptic afferent neurons carrying impulses from bladder by stimulating the nerves of peripheral segmental dermatome (gate control theory of electro modulation by stimulating the peripheral nerves corresponding to the visceral organ). It acts at the level of primitive voiding reflex coordinating the bladder, sphincter and the pelvic floor. Detrusor hyperreflexia can be inhibited by direct inhibition of impulses in the preganglionic afferent neuron or by inhibition of bladder preganglionic neurons of the efferent limb of micturition reflex.
Study NCT03678714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: 2 sessions of supervised exercise training each week for 8 consecutive weeks and 3 sessions of supervised exercise training each week for the final 4 consecutive weeks, at 57-74% heart-rate max. Each session will last approximately 60 minutes.
Study NCT03678714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Physical Activity
Description: Advice and information on how to increase physical activity will be provided. Participants will be asked to monitor and track their daily physical activity using a smart-phone fitness application. The research team will gain permission to access their recorded activity.
Study NCT01327183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Description: at least 1 hour and up to 24 hours after completion of drug infusion
Study NCT01327183 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous Coronary Intervention (PCI)
Description: at least 1 hour and up to 24 hours after completion of drug infusion
Study NCT01327183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4905417
Description: 5 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
Study NCT01327183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4905417
Description: 20 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
Study NCT01327183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: iv infusion, completed at least 1 hour and up to 24 hours before PCI
Study NCT03793972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triage with referral to primary care
Description: During intervention weekends(and holidays) a nurse will triage patients using a newly developped extended Manchester Triage System (eMTS). Patients appropriate for primary care will be referred to the general practitioner on call.We will inform patients about the nature of the intervention using leaflets and broadcasting in the waiting room of the Emergency Department.
Study NCT03793972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: During a control weekend (and holidays), all data registration and collection will be the same as during intervention weekends but patents will not be informed about their allocation advice. The emergency physician will see all patients deciding to stay at the ED, without influence of the triage advice. As in standard clinical care, patients will have the right to change their mind and go spontaneously to the general practitioner. . During control weekends, we will only inform about triage in general but no about the general practioner or the intervention.
Study NCT03853954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Methoxyflurane (Penthrox) inhaler, 3mL inhalation vapour, liquid
Study NCT02525211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: a bolus of 10 ml of ropivacaine 7,5 mg / l then by a diffuser of local anesthesic (Ropivacaine 2mg / ml in continuous flow 10ml / hour) connected on the catheter the day after the intervention before returning at home
Study NCT02525211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: physiological saline
Description: a bolus of 10 ml of physiological saline in the catheter of multi- drilled cicatricial perfusion
Study NCT02564965 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Double Pigtail Plastic Stent
Description: Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
Study NCT02564965 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AXIOS Metal Stent
Description: Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
Study NCT00851877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor
Study NCT00851877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is an anti-cancer chemotherapy drug
Study NCT00851877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: paclitaxel albumin-stabilized nanoparticle formulation
Study NCT00851877 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: intensity-modulated radiation therapy
Study NCT03977272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination drug
Description: Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly
Study NCT03977272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: modified-FOLFIRINOX
Study NCT04123548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: StrataGraft skin tissue
Description: StrataGraft skin tissue was delivered as a single topical application to no more than 3 separate burn sites, totaling up to approximately 2000 cm\^2 of treatment area using no more than 20 tissues.
Study NCT04530656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28
Description: Two doses of middle-dose (20µg/ 0.5ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.
Study NCT04530656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28
Description: Two doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.
Study NCT04530656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28
Description: Three doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28
Study NCT04530656 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Two doses of placebo at the schedule of day 0, 28（middle-dose group）
Description: Two doses of placebo (0.5ml) at the schedule of day 0, 28
Study NCT04530656 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Two doses of placebo at the schedule of day 0, 28（high-dose group）
Description: Two doses of placebo (1.0ml) at the schedule of day 0, 28
Study NCT04530656 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Three doses of placebo at the schedule of day 0, 14, 28（high-dose group）
Description: Three doses of placebo (1.0ml) at the schedule of day 0, 14, 28
Study NCT04889586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG-biofeedback armband (REMO)
Description: After clinical evaluation, the subjects execute an instrumental test. By wearing EMG-biofeedback device (REMO), the subjects have to perform 10 different hand gestures: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The muscle activations (EMG signals) during the execution of each movements, are recorded for 3 seconds.
Study NCT04350723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake Proning
Description: The duration of proning will be a total of 8-10 hours with 1-2 hours break in supine position.
Study NCT02553044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vitamin D3)
Description: Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
Study NCT03047343 — intervention group
Intervention type: OTHER
Intervention: Retrospective data extraction in medical files
Description: Retrospective data extraction in medical files
Study NCT03625115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Navigator (FN)
Description: The intervention will be a modified Patient Navigator model, that we will refer to as a Family Navigator (FN) model, that will engage, inform, and assist participating parents to follow-through with the process of EI referrals and services. Eligible children randomized to the intervention arm will be provided with services from a FN. The FN will maintain contact with the family, the child's primary care provider, and Early Intervention staff, if applicable, throughout the duration of the study.
Study NCT04306952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief MBI
Description: The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat. The rationale for testing the short MBI is to evaluate a low-dose (8 hours of contact) MBI that optimizes cost-effectiveness and minimizes patient burden.
Study NCT04306952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard MBI
Description: The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat. The length of this package is based on the standard length of MBSR as an 8-week program. The rationale for testing the standard MBI is to provide a comparison to a dose (16 hours of contact) that is most similar to the length of MBSR and has the fewest modifications, making it easier to train MBI providers.
Study NCT04306952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended MBI
Description: The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks. Each group session will be two hours. The group sessions will be identical to the standard package except for the timing (every other week) of the last four sessions. In addition to the group sessions, the MBI provider will offer office hours in between the bi-weekly group sessions, where participants will be able to schedule individual sessions with the MBI provider to discuss questions and troubleshoot their mindfulness practice. In addition, participants will receive an all-day meditation retreat, similar to the other conditions. The rationale for testing the extended MBI is to optimize acceptability and uptake based on the investigator's preliminary data by allowing for a slower, extended pace of learning mindfulness practices with an opportunity to have individual discussions with the instructor (16 hours of contact + individual office hours).
Study NCT01599936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anascorp
Description: 3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
Study NCT04600817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ107
Description: QW8
Study NCT04600817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TJ107 placebo
Description: QW8
Study NCT03988881 — intervention group
Intervention type: PROCEDURE
Intervention: Revascularization
Description: PCI or CABG
Study NCT04296643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Mask
Description: Medical Mask (known also as Surgical Mask)
Study NCT04296643 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N95 respirator
Description: N95 respirator
Study NCT03121274 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal delivery
Description: vaginal delivery is carried by an expert obstetrician and the need for forceps or ventose is recorded
Study NCT04119375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keheala Mobile Health Platform and Behavioral Interventions
Description: Keheala is a mobile health company that delivers powerful behavior change interventions from the social sciences across basic feature phones or smartphones to address the nonmedical drivers of disease, which exist away from health facilities.~The intervention includes automated reminders, remote self-verification of doses, accessible TB information and individualized follow-up.
Study NCT04119375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social and Behavior Change Communication (SBCC)
Description: Automated reminders, remote self-verification of doses and accessible TB information. All interactions are behaviorally-informed but do not include regular adherence support/follow-up from study team members as the Keheala intervention does.
Study NCT04119375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Reminder
Description: Patients receive a single daily SMS message to take their medication.
Study NCT04119375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The standard-of-care protocol in Kenya includes diagnosis, the provision of medications - typically administered for a 1-2 week period at which point patients are expected to return to the clinical site - periodic on-the-ground follow-up by community health volunteers (CHVs)(at the discretion of local clinicians and CHVs) and nutritional support, as is sometimes provided.
Study NCT00733850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kanglaite Injection plus gemcitabine
Description: Intravenous repeating dose
Study NCT00733850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Intravenous repeating dose
Study NCT02099669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Blood Cell Transfusions
Study NCT02099669 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cell Transfusions